Abstracts tagged "Inflammation"

Abstract Number: 1329 • ACR Convergence 2021
Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Proton Rahman¹, Iain McInnes², Atul Deodhar³, Georg Schett⁴, Philip Mease⁵, May Shawi⁶, Daniel Cua⁷, Jonathan Sherlock⁸, Alexa Kollmeier⁹, Xie Xu⁷, Yusang Jiang⁷, Shihong Sheng⁷, Christopher Ritchlin¹⁰ and Dennis McGonagle¹¹, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC and University of Oxford, Spring House, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a selective inhibitor of IL-23, significantly improved the diverse manifestations of active psoriatic arthritis (PsA), including dactylitis and enthesitis, in the DISCOVER…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 0025 • ACR Convergence 2021
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Kathrine Pedersen¹, Morten Aagaard Nielsen², Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University / Aarhus University Hopital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
Abstract Number: 0458 • ACR Convergence 2021
Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology
Alisa Mueller¹, Angela Zou¹, Emily Taylor², Triin Major², David Gardner³, Adam Croft⁴, Roche Fibroblast Network Consortium⁵, Andrew Filer², Christopher Buckley⁶, Kevin Wei¹, Ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Birmingham, Birmingham, United Kingdom, ³University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴University of Birmingham, Halesowen, United Kingdom, ⁵Roche Innovation Center Basel, Basel, Switzerland, ⁶University of Oxford, Oxford, United Kingdom, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts are key inflammatory aggressors in rheumatoid arthritis (RA) that mediate cartilage and bone destruction, yet therapies directly targeting these cells are lacking.…
Abstract Number: 0943 • ACR Convergence 2021
Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³ and Monica Guma⁴, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³San Diego VA Healthcare Service, La Jolla, CA, ⁴University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated not simply by progressive degeneration of cartilage, but also by low-grade synovial inflammation (synovitis) that…
Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
Abstract Number: 1767 • ACR Convergence 2021
CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
Xiubo Fan¹, Chin Teck Ng¹, Dianyang Guo¹, Frances Lim¹, Annie Law², Julian Thumboo¹, William Hwang³ and Andrea Low¹, ¹Singapore General Hospital, Singapore, Singapore, ²Singhealth, Singapore, Singapore, ³National Cancer Centre Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease characterized by dysregulation of both innate and adaptive immunity. Current therapeutic options are limited,…
Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: 0096 • ACR Convergence 2020
The Bicipital Stress Test: A Maneuver to More Accurately Diagnose Bicipital Tendinitis and Its Referred Pain Patterns
Meredith Thomley¹, David Spalding², Ana Preda-Naumescu¹ and Raymond Waldrop¹, ¹University of Alabama at Birmingham, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Inflammation of the bicipital tendon contributes heavily to shoulder joint morbidity. To date, diagnosis of bicipital tendinitis has relied on physical exam findings, particularly…
Abstract Number: 0626 • ACR Convergence 2020
Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients
Alisa Mueller¹, Tomoyoshi Tamura², Julia Jezmir³, Erin Penn¹, Gregory Keras⁴, Anthony Massaro⁵ and Edy Kim⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ³Brigham and Women’s Hospital, Department of Medicine, Boston, MA, ⁴Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA
Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…
Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 1118 • ACR Convergence 2020
Bone Marrow Lesion Scores in Patients with Knee Osteoarthritis Undergoing Tibial Osteotomy: Reliability and Concurrent Validity of the Knee Inflammation MRI Scoring System (KIMRISS)
Jenna Schulz¹, Trevor Birmingham¹, Walter Maksymowych², Robert G Lambert³, Stephany Pritchett⁴, Frank Beier¹, J. Robert Giffin⁵ and Tom Appleton⁶, ¹Western University, London, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ⁴London Health Sciences Centre, London, Canada, ⁵Western University and London Health Sciences Centre, London, Canada, ⁶The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Bone marrow lesions (BMLs) commonly occur in knee osteoarthritis (OA) and are associated with increased risk of cartilage damage and pain. The Knee Inflammation…
Abstract Number: 1519 • ACR Convergence 2020
Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
Sijia Chen¹, Catherine Manning², Melissa van Tok³, Yukiko Maeda⁴, Daniel Montoro⁵, Jung-Min Kim⁶, Jeroen den Dunnen³, Nataliya Yeremenko³, Jae-Hyuck Shim⁴, Dominique Baeten⁷ and Ellen Gravallese⁸, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women’s Hospital, Boston, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴University of Massachusetts Medical School, worcester, MA, ⁵Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, ⁶University of Massachusetts Medical School, Worcester, ⁷UCB Pharma / Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interleukin(IL)-17D is a little recognized member of the IL-17 family of cytokines. While the activities of IL-17A and IL-17F in the pathogenesis of spondyloarthritis…
Abstract Number: 1855 • ACR Convergence 2020
Elevated Calprotectin Levels Reveal Loss of Vascular Pattern and Atrophy of Villi in Ileum Using Digital Chromo-endoscopy and Magnification Colonoscopy in Patients with Spondyloarthritis Without Inflammatory Bowel Disease
Consuelo Romero-Sanchez¹, Cristian Florez-Sarmiento², Valerie Khoury-Rosas³, Wilson Bautista-Molano⁴, Magaly Chamorro-Melo⁵, Diego Alejandro Jaimes⁶, Adriana Beltran-Ostos⁷, Juliette De Avila⁸, Alejandro Ramos-Casallas⁸, Juan Manuel Bello-Gualtero⁹, Jaiber Gutierrez⁵, Cesar Pacheco Tena¹⁰, Philipe Chalem Choueka¹¹ and Viviana Parra-Izquierdo¹², ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo- / Grastroadvanced SAS, Bogotá D.C., Colombia, ³Universidad EL Bosque / School of Medicine, Bogotá D.C., Colombia, ⁴University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ⁵Hospital Militar Central, Rheumatology and Immunology Department, School of Medicine, Bogotá D.C., Colombia, ⁶Clínicos IPS- Universidad de la Sabana, Bogotá D.C., Colombia, ⁷Hospital Militar Central, Subdirección de docencia e Investigación, Bogotá D.C., Colombia, ⁸Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ⁹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ¹⁰Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ¹¹Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ¹².Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo- / Grastroadvanced SAS, Bogotá D.C., Colombia
Background/Purpose: Fecal calprotectin (FC) is a well bio-marker related to mucosal inflammation. Digital chromo-endoscopy (DCE) with magnification is a technique to identify microscopic inflammation. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].